SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 1996
BIOPHARMACEUTICS, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 1-9370 13-3186327
(State or other (Commission File Number) (I.R.S Employer
jurisdiction of I.D. Number)
incorporation)
990 Station Road
Bellport, New York 11713
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (516) 286-5800
N/A
(Former name or former address, if changed since last report.)
1
<PAGE>
ITEM 5. OTHER EVENTS
On September 25, 1996 the Company signed a Joint Venture Agreement
with Advanced Biological Systems, Inc. to commercialize Mitolactol*
Biopharmaceutics' cancer drug. Advanced will pay Biopharmaceutics a minimum of
$2,750,000 in cash and stock to participate in the Joint Venture and fund the
approximately $1,000,000 cost associated with the final development of
Mitolactol.
EXHIBIT INDEX
Current Report on Form 8-K
of
Biopharmaceutics, Inc.
Date of Report: October 9, 1996
Exhibits:
28.14 Joint Venture Agreement dated September 25, 1996
* Registered Trademark
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHARMACEUTICS, INC.
(Registrant)
By: /s/ Edward Fine
--------------------
Edward Fine
President, Chief Executive Officer
(Signature)
Dated: October 9, 1996
3
<PAGE>
